• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Covid-19 Antibodies Found in Nonimmune Blood Cancer Patients After Receiving Booster

Article

Patients with blood cancers have been reported to have less of a chance to develop immunity from the COVID-19 vaccination. However, new data has been found stating those who have been previously vaccinated with no immunity and then followed up with a booster dose, eventually developed antibodies against the virus.

Patients with blood cancers have been reported to have less of a chance to develop immunity from the COVID-19 vaccination. However, new data has been found stating those who have been previously vaccinated with no immunity and then followed up with a booster dose, eventually developed antibodies against the virus.

This data is based off of a study that was published in July in the American Cancer Society's journal, Cancer.

Authors of the study retrospectively analyzed serologic responses to initial and booster COVID-19 vaccination in 378 patients with hematologic malignancy, or blood cancers such as leukemia, lymphoma and multiple myeloma, and subsequently tracked COVID-19–related outcomes.

Antibodies were found in 181 patients after initial vaccination; patients who had active malignancy or those who were recently treated with a B-cell–depleting monoclonal antibody had the lowest rates of developed antibodies, the study said.

For initial nonresponders to the vaccination, immunity after a booster dose occurred in 48 of 85 patients (56%). The seroconversion or immunity rate after the booster was similar for patients on (53%) and off (58%) active therapy.

Results from the study also found 33 patients (8.8%) developed a COVID-19 infection, and three succumed to COVID-19–related deaths (0.8%).

Researchers found that post-vaccination antibody response may not be associated with a decrease in any COVID-19 infection. They suggested effective vaccination with a booster, supplemented by passive immunization using tixagevimab/cilgavimab in case of lack of seroconversion, effectively in the otherwise high-risk population.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.